1. Statins Increase Rifampin Mycobactericidal Effect
- Author
-
Lobato, Lívia Silva, Rosa, Patrícia Sammarco, Ferreira, Jessica da Silva, Neumann, Arthur da Silva, da Silva, Marlei Gomes, do Nascimento, Dejair Caitano, Soares, Cleverson Teixeira, Pedrini, Silvia Cristina Barbosa, Oliveira, Diego Sá Leal de, Monteiro, Cláudia Peres, Pereira, Geraldo Moura Batista, Ribeiro-Alves, Marcelo, Hacker, Mariana Andrea, Moraes, Milton Ozório, Pessolani, Maria Cristina Vidal, Duarte, Rafael Silva, and Lara, Flávio Alves
- Abstract
ABSTRACTMycobacterium lepraeand Mycobacterium tuberculosisantimicrobial resistance has been followed with great concern during the last years, while the need for new drugs able to control leprosy and tuberculosis, mainly due to extensively drug-resistant tuberculosis (XDR-TB), is pressing. Our group recently showed that M. lepraeis able to induce lipid body biogenesis and cholesterol accumulation in macrophages and Schwann cells, facilitating its viability and replication. Considering these previous results, we investigated the efficacies of two statins on the intracellular viability of mycobacteria within the macrophage, as well as the effect of atorvastatin on M. lepraeinfections in BALB/c mice. We observed that intracellular mycobacteria viability decreased markedly after incubation with both statins, but atorvastatin showed the best inhibitory effect when combined with rifampin. Using Shepard's model, we observed with atorvastatin an efficacy in controlling M. lepraeand inflammatory infiltrate in the BALB/c footpad, in a serum cholesterol level-dependent way. We conclude that statins contribute to macrophage-bactericidal activity against Mycobacterium bovis, M. leprae, and M. tuberculosis. It is likely that the association of statins with the actual multidrug therapy effectively reduces mycobacterial viability and tissue lesion in leprosy and tuberculosis patients, although epidemiological studies are still needed for confirmation.
- Published
- 2014
- Full Text
- View/download PDF